Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
Diagnostic Advances in gMG: Effective Tools and Techniques
Vera Bril, MD
Hans Katzberg, MD
Living with gMG: Navigating Personal, Professional, and Mental Health Challenges
Nicholas J. Silvestri, MD
Precision Medicine for gMG: Tailoring Treatments Based on Patient Profiles
A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained
Traditional MG Treatments: Balancing Benefits, Risks, and Side Effect Management
Non-CF Bronchiectasis: How Radiologists Can Drive Better Outcomes
April 29, 2025
San Diego, California
Collaborative Insights to Solve the Puzzle of Bladder Cancer
Daniel P. Petrylak, MD
Elizabeth R. Plimack, MD, MS, FASCO
Evan Y. Yu, MD
Personalizing Care Within the RCC Treatment Paradigm
Eric Jonasch, MD
Brad McGregor, MD
Ulka Vaishampayan, MBBS
Treatment Advances in Generalized Myasthenia Gravis: Addressing the Nuances of its Underlying Immunopathology
Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection
Jonathan Strober, MD
Managing Side Effects in FcRn Therapy: Best Practices for gMG
Driving Progress in Cardiology: Exploring the Role of FXI in Acute Coronary Syndromes & Beyond
May 01, 2025
Washington, DC, District of Columbia
Chairperson’s Perspective: Treating At-Risk MASH: What Are You Waiting For?
Mazen Noureddin, MD, MHSc
New Solutions for Optimizing IOP Control: A Case-Based Approach
Sarah H. Van Tassel, MD
Justin Schweitzer, OD, FAAO
Ocular to Generalized MG: How and Why the Disease Evolves
What’s New in Schlemm’s Canal MIGS?
Paul Petrakos, DO, MS
I. Paul Singh, MD
What’s New in Glaucoma Therapy?
What’s New With 3D Visualization in Glaucoma Surgery?
What’s New in Subconjunctival MIBS
3D Heads-Up Visualization: Tips for Getting Started in Glaucoma Surgery
Autoantibodies Explained: Anti-AChR, Anti-MuSK, and Their Diagnostic Role
What’s New in Suprachoroidal MIGS?
3D Heads-Up Visualization: Cases in Glaucoma Surgery
Recent Updates on Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
Sandra Swain, MD
Virginia Kaklamani, MD
Duration of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
Future Directions of Ovarian Function Suppression: Answering Unmet Needs in Premenopausal HR+ Early-Stage Breast Cancer
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.